Neurology Specific Literature Search   
 
[home][thesaurus]
    
Click Here to return To Results

 

B-Cell Depletion with Rituximab in Relapsing-Remitting Multiple Sclerosis
NEJM 358:676-688, Hauser,S.L.,et al, 2008
See this aricle in Pubmed

Article Abstract
A single course of rituximab reduced inflammatory brain lesions and clinical relapses for 48 weeks. This trial was not designed to assess long-term safety or to detect uncommon adverse events. The data provide evidence of ?-cell involvement in the pathophysiology of relapsing-remitting multiple sclerosis.
 
Related Tags
(click to filter results - removes previous filter)

adverse drug reaction
B cell lymphocyte depletion
B cell lymphocytes
gadolinium
monoclonal antibodies
MRI
MRI,abnormal
MRI,contrast enhanced
MRI,demyelinating disease
multiple sclerosis
multiple sclerosis,pathogenesis
multiple sclerosis,relapsing
multiple sclerosis,treatment of
rituximab
safety
treatment of neurologic disorder

Click Here to return To Results